AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Nuvectis Pharma Statistics
Share Statistics
Nuvectis Pharma has 19.32M shares outstanding. The number of shares has increased by 8.74% in one year.
Shares Outstanding | 19.32M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 3.58% |
Owned by Institutions (%) | n/a |
Shares Floating | 8.28M |
Failed to Deliver (FTD) Shares | 1.74K |
FTD / Avg. Volume | 0.94% |
Short Selling Information
The latest short interest is 1.44M, so 7.48% of the outstanding shares have been sold short.
Short Interest | 1.44M |
Short % of Shares Out | 7.48% |
Short % of Float | 16.27% |
Short Ratio (days to cover) | 6.98 |
Valuation Ratios
The PE ratio is -5.83 and the forward PE ratio is -11.44.
PE Ratio | -5.83 |
Forward PE | -11.44 |
PS Ratio | 0 |
Forward PS | 36.9 |
PB Ratio | 10.63 |
P/FCF Ratio | -8.13 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Nuvectis Pharma Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.
Current Ratio | 2.75 |
Quick Ratio | 2.75 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.82% and return on capital (ROIC) is -187.66%.
Return on Equity (ROE) | -1.82% |
Return on Assets (ROA) | -1.16% |
Return on Capital (ROIC) | -187.66% |
Revenue Per Employee | 0 |
Profits Per Employee | -1.71M |
Employee Count | 13 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -23.65% in the last 52 weeks. The beta is 0.4, so Nuvectis Pharma 's price volatility has been higher than the market average.
Beta | 0.4 |
52-Week Price Change | -23.65% |
50-Day Moving Average | 5.86 |
200-Day Moving Average | 6.53 |
Relative Strength Index (RSI) | 51.7 |
Average Volume (20 Days) | 185.16K |
Income Statement
Revenue | n/a |
Gross Profit | -22.90M |
Operating Income | -22.90M |
Net Income | -22.26M |
EBITDA | -22.90M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.43 |
Balance Sheet
The company has 19.13M in cash and 0 in debt, giving a net cash position of 19.13M.
Cash & Cash Equivalents | 19.13M |
Total Debt | 0 |
Net Cash | 19.13M |
Retained Earnings | -54.24M |
Total Assets | 17.31M |
Working Capital | 10.99M |
Cash Flow
In the last 12 months, operating cash flow was -15.95M and capital expenditures 0, giving a free cash flow of -15.95M.
Operating Cash Flow | -15.95M |
Capital Expenditures | 0 |
Free Cash Flow | -15.95M |
FCF Per Share | -1.03 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
NVCT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -25.31% |
FCF Yield | -14.62% |
Analyst Forecast
The average price target for NVCT is $21, which is 271.7% higher than the current price. The consensus rating is "Buy".
Price Target | $21 |
Price Target Difference | 271.7% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Scores
Altman Z-Score | 1.67 |
Piotroski F-Score | 1 |